Quick Answer
Inhibitor Therapeutics, Inc. reported Research And Development Expense of $1.70 million for the year ending 2025.
- Inhibitor Therapeutics, Inc. showed a decrease of -3.5% in Research And Development Expense from 2024 to 2025.
- This data is from Inhibitor Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Inhibitor Therapeutics, Inc.'s Research And Development Expense has grown by 59.3%.
- Historical annual values: Fiscal year 2025: $1.70 million | Fiscal year 2024: $1.76 million | Fiscal year 2023: $1.38 million | Fiscal year 2022: $6.2 thousand | Fiscal year 2021: $4.9 thousand | Fiscal year 2020: $185.3 thousand | Fiscal year 2019: $1.21 million | Fiscal year 2018: $2.63 million | Fiscal year 2017: $2.23 million | Fiscal year 2016: $2.64 million | Fiscal year 2015: $1.68 million | Fiscal year 2014: $2.43 million | Fiscal year 2013: $1.07 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: